Mallinckrodt plc
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mallinckrodt plc (NYSE: MNK), now operating as Keenova Therapeutics following a major restructuring, develops, manufactures and commercializes branded specialty pharmaceuticals focused on rare and unaddressed medical conditions across immunology, urology, hepatology, ophthalmology, orthopedics, rheumatology, nephrology, pulmonology, neurology and critical care; its core products include Acthar Gel, a repository corticotropin injection for inflammatory and autoimmune disorders such as infantile spasms and multiple sclerosis exacerbations, and XIAFLEX, a nonsurgical collagenase clostridium histolyticum injection for Dupuytren's contracture and Peyronie's disease, alongside Terlivaz for hepatorenal syndrome and other branded therapies in endocrinology, gastroenterology and neonatal respiratory care. The company, founded in 1867 and headquartered in Dublin, Ireland, with operational headquarters and manufacturing facilities in the United States including Louisiana, New Jersey, New York, Pennsylvania and Wisconsin, primarily serves the U.S. healthcare system, where the majority of its revenues originate. Keenova Therapeutics employs over 1,600 team members and generated pro forma combined 2024 revenue of $1.7 billion from its diversified branded portfolio. In recent developments, Mallinckrodt completed its merger with Endo Inc. on August 1, 2025, in a $6.7 billion transaction that combined their specialty portfolios, with Mallinckrodt shareholders owning 50.1% of the entity on a pro forma basis; this followed significant progress including SEC registration effectiveness, HSR clearance and shareholder approval in June 2025. On November 10, 2025, the company spun off its Par Health generic pharmaceuticals, sterile injectables and active pharmaceutical ingredients businesses as an independent entity, enabling Keenova Therapeutics to concentrate exclusively on branded therapeutics while planning a New York Stock Exchange listing and public equity offering in 2026. Earlier, in August 2024, Mallinckrodt sold its Therakos immunotherapy business to CVC Capital Partners for $925 million to reduce debt and streamline operations.
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan
Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)
Buxton Helmsley Issues Statement on Mallinckrodt plc. Bankruptcy Filing and Disclosures Revealing Apparently Concealed Intangible Asset Depreciation Expenses
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations
NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
Mallinckrodt discloses grand jury subpoena, makes bankruptcy filing official
Drugmaker Mallinckrodt files for second bankruptcy in the US
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations
MALLINCKRODT SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options
Mallinckrodt stock tumbles on plans to file for Chapter 11 bankruptcy for second time in three years
MNK Stock Alert: Mallinckrodt Files for Bankruptcy Again
U.S. drugmaker Mallinckrodt plans to file for bankruptcy protection
Mallinckrodt to file for prepackaged Chapter 11 bankruptcy and cut about $1.9 billion in debt